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MicroarrayIntrahepatic cholangiocarcinoma (ICC) is an aggressive cancer, arising in the biliary ducts that extend into the liver.
The highest incidence of ICC occurs in Southeast Asia, particularly in the Mekong River Basin countries of Thailand,
Laos, Cambodia, and Vietnam, where it is strongly associated with chronic infection by the food-borne liver ﬂuke
Opisthorchis viverrini (OV), one of only three eukaryote pathogens considered Group one carcinogens. Intrahepatic
cholangiocarcinoma is usually diagnosed at an advanced stage, with a poor prognosis and survival often less than
24 months. Hence, biomarkers that enable the early detection of ICC would be desirable and have a potentially im-
portant impact on the public health in the resource-poor regionswhere this cancer ismost prevalent. AsmicroRNAs
(miRNAs) remain well preserved after formalin ﬁxation, there is much interest in developing them as biomarkers
that can be investigated using tumor biopsy samples preserved in formalin ﬁxed parafﬁn embedded (FFPE)
tumor blocks. Recently, we reported the ﬁrst comprehensive proﬁling of tissue-based miRNA expression using
FFPE from the three most common subtypes of OV-induced ICC tumors: moderately differentiated ICC, papillary
ICC, and well-differentiated ICC.We observed that each subtype of OV-induced ICC exhibited a distinct miRNA pro-
ﬁle, which suggested the involvement of speciﬁc sets of miRNAs in the progression of this cancer. In addition, non-
tumor tissue adjacent to ICC tumor tissue on the same FFPE block shared a similarmiRNA dysregulation proﬁle with
the tumor tissue than with normal (non-tumor) liver tissue (individuals without ICC or OV infection). Herein,
we provide a detailed description of the microarray analysis procedures used to derive these ﬁndings.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).Speciﬁcations (continued)SpeciﬁcationsOrganism/cell line/tissue Homo sapiens
Sex 11 males 18 females
Sequencer or array type GPL#18159: Agilent-031181 Unrestricted Hu-
man miRNA version 16.0 Microarray
Data format Raw and Processed
Experimental factors Three histological grades of Intrahepatic
cholangiocarcinoma (ICC) tumor vs. distal
non-tumor sections (from the ICC patient) vs.
non-ICC “normal” liver biopsy FFPE.Experimental features miRNA expression in FFPE samples of threeogy, Immunology and Tropical
eorge Washington University,
1 202 994 2913.
. This is an open access article under the CC BY license (http://creativecommhistological grades of ICC tumor tissues when
compared to both distal non-tumor samples
(from the same ICC patients) and also non-
endemic, non-ICC, “normal” liver biopsies.Consent Institutional Review Board reviewed
Sample source location Thailand; Washington D.C., United StatesDirect link to deposited data
Deposited data can be found here: http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE53992.ons.org/licenses/by/3.0/).
Table 1
Intrahepatic cholangiocarcinoma (ICC) FFPE cases utilized in the study denoted with associated raw data ﬁles and accession numbers. Distal tumor (D-NT) and tumor (CTT) samples types are indicated for each case.
NCBI accession number Title Sample type Sex Age Tumor histological grade Gross Classiﬁcation Raw intensity ﬁles
GSM1305122 B70-N1 Distal normal Male 61 Well differentiated Mass-forming GSM1305122_US12302349_253118113117_S01_miRNA_1100_Jul11_1_3.txt.gz
GSM1305123 B70-T1 Tumor GSM1305123_US12302349_253118113117_S01_miRNA_1100_Jul11_1_4.txt.gz
GSM1305124 B79-N1 Distal normal Male 61 Well differentiated Periductal inﬁltrating,
invasive intraductal and mixed
GSM1305124_US12302349_253118113117_S01_miRNA_1100_Jul11_2_1.txt.gz
GSM1305125 B79-T1 Tumor GSM1305125_US12302349_253118113117_S01_miRNA_1100_Jul11_2_2.txt.gz
GSM1305126 B83-N1 Distal normal Female 53 Well differentiated Mass-forming GSM1305126_US12302349_253118113117_S01_miRNA_1100_Jul11_2_3.txt.gz
GSM1305127 B83-T1 Tumor GSM1305127_US12302349_253118113117_S01_miRNA_1100_Jul11_2_4.txt.gz
GSM1305108 B99-N1 Distal normal Male 48 Well differentiated Mass-forming GSM1305108_US12302349_253118112956_S01_miRNA_1100_Jul11_2_1.txt.gz
GSM1305109 B99-T1 Tumor GSM1305109_US12302349_253118112956_S01_miRNA_1100_Jul11_2_2.txt.gz
GSM1305110 Y42-N1 Distal normal Male 61 Well differentiated Mass-forming GSM1305110_US12302349_253118112956_S01_miRNA_1100_Jul11_2_3.txt.gz
GSM1305111 Y42-T1 Tumor GSM1305111_US12302349_253118112956_S01_miRNA_1100_Jul11_2_4.txt.gz
GSM1305106 B90-N1 Distal normal Male 58 Well differentiated Mass-forming GSM1305106_US12302349_253118112956_S01_miRNA_1100_Jul11_1_3.txt.gz
GSM1305107 B90-T1 Tumor GSM1305107_US12302349_253118112956_S01_miRNA_1100_Jul11_1_4.txt.gz
GSM1305100 B91-Nec1 Necrotic Male 63 Moderately differentiated Mass forming GSM1125485_US12302349_253118112871_S01_miRNA_107_Sep09_2_1.txt.gz
GSM1305101 B91-T1 Tumor GSM1125486_US12302349_253118112871_S01_miRNA_107_Sep09_2_2.txt.gz
GSM1305102 Y70-N1 Distal normal Female 63 Moderately differentiated Mass forming GSM1125487_US12302349_253118112871_S01_miRNA_107_Sep09_2_3.txt.gz
GSM1305103 Y70-T1 Tumor GSM1125488_US12302349_253118112871_S01_miRNA_107_Sep09_2_4.txt.gz
GSM1305116 Y56-N1 Distal normal Female 56 Papillary carcinoma Periductal inﬁltrating,
invasive intraductal and mixed
GSM1305116_US12302349_253118112957_S01_miRNA_1100_Jul11_2_1.txt.gz
GSM1305117 Y56-T1 Tumor GSM1305117_US12302349_253118112957_S01_miRNA_1100_Jul11_2_2.txt.gz
GSM1305118 Y62-N1 Distal normal Male 57 Papillary carcinoma Periductal inﬁltrating,
invasive intraductal and mixed
GSM1305118_US12302349_253118112957_S01_miRNA_1100_Jul11_2_3.txt.gz
GSM1305119 Y62-T1 Tumor GSM1305119_US12302349_253118112957_S01_miRNA_1100_Jul11_2_4.txt.gz
GSM1305114 B40-N1 Distal normal Male 64 Papillary carcinoma Mass forming GSM1305114_US12302349_253118112957_S01_miRNA_1100_Jul11_1_3.txt.gz
GSM1305115 B40-T1 Tumor GSM1305115_US12302349_253118112957_S01_miRNA_1100_Jul11_1_4.txt.gz
GSM1305129 Y83-N1 Distal normal Female 51 Papillary carcinoma Mass forming GSM1305129_US12302349_253118113118_S01_miRNA_1100_Jul11_1_2.txt.gz
GSM1305130 Y83-T1 Tumor GSM1305130_US12302349_253118113118_S01_miRNA_1100_Jul11_1_3.txt.gz
GSM1305131 Y88-N2 Distal normal Female 58 Papillary carcinoma Periductal inﬁltrating,
invasive intraductal and mixed
GSM1305131_US12302349_253118113118_S01_miRNA_1100_Jul11_1_4.txt.gz
GSM1305132 Y88-T1 Tumor GSM1305132_US12302349_253118113118_S01_miRNA_1100_Jul11_2_1.txt.gz
GSM1305133 Y89-N Distal normal Female 60 Papillary carcinoma Mass forming GSM1305133_US12302349_253118113118_S01_miRNA_1100_Jul11_2_2.txt.gz
GSM1305134 Y89-Nerc Necrotic GSM1305134_US12302349_253118113118_S01_miRNA_1100_Jul11_2_3.txt.gz
GSM1305135 Y89-T Tumor GSM1305135_US12302349_253118113118_S01_miRNA_1100_Jul11_2_4.txt.gz
GSM1305138 Y93-N1 Distal normal Male 63 Papillary carcinoma Periductal inﬁltrating,
invasive intraductal and mixed
GSM1305138_US12302349_253118113119_S01_miRNA_1100_Jul11_1_3.txt.gz
GSM1305139 Y93-T1 Tumor GSM1305139_US12302349_253118113119_S01_miRNA_1100_Jul11_1_4.txt.gz
GSM1305140 Y96-N1 Distal normal Female 64 Papillary carcinoma Mass forming GSM1305140_US12302349_253118113119_S01_miRNA_1100_Jul11_2_1.txt.gz
GSM1305141 Y96-T1 Tumor GSM1305141_US12302349_253118113119_S01_miRNA_1100_Jul11_2_2.txt.gz
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Table 2
Additional FFPE cases, normal non-tumor tissue (N-NT) from non-ICC gastric bypass patients, utilized in the study denoted with raw data ﬁle names and accession numbers.
NCBI accession number Title Sample Type Raw intensity ﬁles
GSM1305096 3325A Non-ICC, N-NT GSM1305096_US12302349_253118112955_S01_miRNA_1100_Jul11_1_1.txt.gz
GSM1305097 3337A Non-ICC, N-NT GSM1305096_US12302349_253118112955_S01_miRNA_1100_Jul11_1_2.txt.gz
GSM1305098 3356A Non-ICC, N-NT GSM1305096_US12302349_253118112955_S01_miRNA_1100_Jul11_1_3.txt.gz
GSM1305099 3377A Non-ICC, N-NT GSM1305096_US12302349_253118112955_S01_miRNA_1100_Jul11_1_4.txt.gz
GSM1305104 3575A Non-ICC, N-NT GSM1305104_US12302349_253118112956_S01_miRNA_1100_Jul11_1_1.txt.gz
GSM1305105 3578A Non-ICC, N-NT GSM1305105_US12302349_253118112956_S01_miRNA_1100_Jul11_1_2.txt.gz
GSM1305112 3641A Non-ICC, N-NT GSM1305112_US12302349_253118112957_S01_miRNA_1100_Jul11_1_1.txt.gz
GSM1305113 3707A Non-ICC, N-NT GSM1305113_US12302349_253118112957_S01_miRNA_1100_Jul11_1_2.txt.gz
GSM1305120 3563A Non-ICC, N-NT GSM1305120_US12302349_253118113117_S01_miRNA_1100_Jul11_1_1.txt.gz
GSM1305121 3564A Non-ICC, N-NT GSM1305121_US12302349_253118113117_S01_miRNA_1100_Jul11_1_2.txt.gz
GSM1305128 3869A Non-ICC, N-NT GSM1305128_US12302349_253118113118_S01_miRNA_1100_Jul11_1_1.txt.gz
GSM1305136 3967A Non-ICC, N-NT GSM1305136_US12302349_253118113119_S01_miRNA_1100_Jul11_1_1.txt.gz
GSM1305137 4565A Non-ICC, N-NT GSM1305137_US12302349_253118113119_S01_miRNA_1100_Jul11_1_2.txt.gz
276 J. Peng et al. / Genomics Data 2 (2014) 274–279Experimental design, materials and methods
Study samples
Intrahepatic cholangiocarcinoma (ICC) formalin-ﬁxed, parafﬁn-
embedded tissues (FFPE) were obtained from histologically conﬁrmed
O. viverrini (OV) induced ICC cases archived at the Liver Fluke and
Cholangiocarcinoma Research Center, Faculty of Medicine, Khon Kaen
University (KKU), Thailand (Table 1). The histological subtypes of ICC
cases were determined by Hematoxylin and Eosin (H & E) staining of
tissue by pathologists at KKU (BS) and independently conﬁrmed by
a pathologist (SEE) at the George Washington University (GWU).
The ICC FFPE blocks were then macrodissected into ICC tumor tissue
(cholangiocarcinoma tumor tissue or CTT) and distal non-tumor
(D-NT) tissue (i.e. tissue distal from dysplasia or frank carcinoma). In
addition, 13 non-tumor FFPE blocks (Table 2) derived from liver biopsies
of individuals suspected of severe steatosis or steatohepatitis prior to
gastric bypass surgery were included as normal non-tumor tissue
(N-NT) to assess baseline liver histology of individuals with no ICC and
do not reside in an OV endemic region. Details of the specimens, includ-
ing histological conﬁrmation and preparation of FFPE samples, can be
found in [1].
The Institutional Review Boards from both KKU and GWU deter-
mined that the samples did not meet the deﬁnition of human subjects
research, i.e., a living individual about whom an investigator conducting
research obtains: a) data through intervention or interaction with the
individual or b) private identiﬁable information. This determination
was made since the samples were limited to pre-existing, de-identiﬁed
specimen analysis labeled with a random code.
RNA isolation
Total RNA was extracted from each of the FFPE blocks using the
miRNeasy FFPE kit (Qiagen) following the manufacturer's protocol [2]
and also further detailed in [1]. RNA quality and integrity were exam-
ined by spectrophotometry (Nano Drop 2000, Thermo Scientiﬁc) and
by using an Agilent 2100 Bioanalyzer (RNA 6000 Nano and Small RNA
Kits, Agilent). The 260/280 ratios obtained were approximately 2.0,
indicating that the RNA was pure. The puriﬁed RNA exhibited 260/230
ratios greater than 1.9, or only slightly less than the range of 2.0–2.2
expected, indicating no signiﬁcant contaminants.
Analysis by theAgilent Bioanalyzer producedRNA integrity numbers
(or RIN scores) of two to three, with 28S and 18S peaks largely absent.
This value was below the quality criteria (RIN greater than or equal to
eight) and indicated degraded RNA. RNA obtained from FFPE tissue
samples often has slight modiﬁcations and degradation due to the
process of formalin ﬁxation and duration of storage is expected [3,4].
However, due to the stable nature of miRNAs in the FFPE matrix, as
shown by us [1,2] as well as others [5,6], the extracted RNA wasdetermined to be suitable for subsequent analysis of miRNA proﬁles
by microarray.
Microarray analysis
Puriﬁed RNA from all 46 cases samples including 16 CTT and both
types of controls (15, D-NT and 13, N-NT) (Tables 1, 2) were proﬁled
on the Agilent human miRNA microarray (miRBase Release 16.0).
Hybridization and further details are available in the Gene Expression
Omnibus (GEO) database and also found in [1].
Data normalization and analysis
The feature intensity of each sample was transferred to digital data
and then log2 transformed using Agilent Feature Extraction (V.10.7).
All the raw data ﬁles in text (.txt) format were analyzed (including
statistical analysis) with Agilent GeneSpring software (GX 12.6)
(http://genespring-support.com/ﬁles/gs_12_6/GeneSpring-manual.pdf)
[7].
To determine the presence of aberrantly expressed miRNAs, a
new “project” and new “experiment” were created within GeneSpring
(GX 12.6), with miRNA selected for analysis type and the data import
wizard used for the workﬂow type. After uploading the raw intensity
ﬁles into GeneSpring, 31181_v18_0 technology was selected (Table 3).
The threshold raw signals were set to 1.0 and 90 percentile and “shift
normalization”was performed to standardize the statistical parameters
across all samples (Table 3). No baseline transformationwas performed.
Four different methods were used to analyze this sample set as
shown in Fig. 1 and in Table 3. Dysregulated miRNAs were reported
as associated with either ICC itself or with ICC stratiﬁed by histological
subtype as reported in [1].
• Analysis One: Normal, non-tumor tissues (N-NT), distal normal tissues
(D-NT), and ICC tumor tissues (CCT) samples were analyzed with 3D
Principal Components Analysis (PCA), Hierarchical Clustering, and
One-way analysis of variance (ANOVA).
• Analysis Two: Paired Student's t-test was used to analyze CTT versus
D-NT stratiﬁed by the histological subtype of ICC.
• Analysis Three: Unpaired Student's t-test was used to analyze each
histological subtype of ICC tumor (including CTT, D-NT and when
available necrotic tissue) versus N-NT, (non-ICC normal, non-tumor
tissue).
• Analysis Four: One-way ANOVA was used to analyze the differences
among the three histological subtypes of ICC FFPE samples (including
CTT, necrotic tissue and D-NT).
In all analyses below, subsequent “interpretations” were created
in GeneSpring (GX 12.6) with the conditions selected, including “non-
averaged” selected over replicates, and the measurements ﬂagged as
“default.” In most analyses, unless otherwise noted, the probe sets
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277J. Peng et al. / Genomics Data 2 (2014) 274–279were ﬁltered by expression value (i.e. 30–336133.0) with at least 50% of
the values greater than 30 in any one condition within range.
Analysis One: CTT versus N-NT versus D-NT by one-way ANOVA
1) In this ﬁrst experimental design (Table 3), the FFPE samples were
grouped accordingly: 13 N-NT, 15 D-NT, 2 necrotic samples, and
16 CCT samples (without consideration of histological subtype).
2) For “Quality Control”, the correlation coefﬁcient (CC) and3DPrincipal
Component Analysis (PCA) scores were used to determine associa-
tions among the samples. The CC of sample Y62-N1 (D-NT from
a papillary ICC block) was below an acceptable CC (b0.7) and the
sample removed from subsequent analyses. Principle Components
Analysis demonstrated that N-NT samples clustered together, and
were distinct from the other types of samples (CTT andD-NT). Further
details regarding principal component analysis can be found below:
• Algorithm: Principal Components Analysis
• Parameters:
○ Column indices: [1–45]
○ Pruning option: [numPrincipalComponents, [4]]
○ Mean centered: True
○ Scale: True
○ 3-D scores: True
○ PCA on: Columns
3) Hierarchical Clustering analysis of the samples' correlationswas then
conducted on both “entities” and “conditions” on the normalized
intensity values after ﬁltering by Euclidean distance metric and
Median linkage rule. Hierarchical Clustering details are summarized
below:
• Clustering Algorithm: Hierarchical
• Clustered By: Normalized intensity values
• Clustered On: Entities and Conditions
• Similarity Measure: Euclidean
• Linkage Rule: Median
• Cluster Within Conditions: No
4) To analyze the differences between CTT versus D-NT versus N-NT, a
one-way ANOVAwas conducted (with no post hoc pairwise testing)
with asymptotic p-value computation without correction complet-
ed. Fold changes (≥2.0) were analyzed under pairs of conditions
with two minimum numbers of pairs. Fewer differences were
observed between tumor tissue (CTT) and distal non-tumor tissue
(D-NT) than between D-NT and N-NT, conﬁrming the PCA and
Hierarchical Clustering results.
Analysis Two: CTT versus D-NT by paired Student's t-test
1) CTT samples were again grouped by histological subtype and
compared to adjacent non-tumor tissue (D-NT) (see Table 1):
i.e., moderately differentiated CTT versus D-NT from the same
block, well-differentiated CTT versus D-NT from the same block,
and papillary CTT versus D-NT from the same block (Table 3,
Box 2 Fig. 1).
2) To ﬁlter probe sets by expression value, in each case the “entity”
and “interpretation” were selected and ﬁltered by raw data
values. The lower cut-off value was set to 30 and at least 50% of
the values in any one condition within range for well-
differentiated CTT versus its D-NT and papillary CTT versus
its D-NT. In the case of moderately differentiated CTT versus
necrosis versus N-NT, at least 50% of the values in one condition
were greater than 20.
Fig. 1. Flow diagram of analyses and associated miRNAs found to be dysregulated. A ﬁnal qPCR veriﬁcation step was also completed to conﬁrm the magnitude and expression levels
determined by microarray but not described herein [1]. A Venn diagram [8] highlights overlapping miRNAs identiﬁed in analysis three and analysis four, yielding seven overlapping
miRNAs. Abbreviations are as follows: Intrahepatic cholangiocarcinoma tumor tissue (CTT); distal non-tumor tissue (D-NT); and normal non-tumor tissue (N-NT).
278 J. Peng et al. / Genomics Data 2 (2014) 274–2793) In the “analysis workﬂow” in GeneSpring (GX 12.6), paired
Student's t-test (p b 0.05) was performed to analyze differences
among CTT versus D-NT samples of well-differentiated ICC
and papillary ICC by asymptotic p-value computation without
correction for multiple testing. Further a fold change cut-off of
2.0 between conditions (CTT against D-NT) was performed.
Only fold changes≥ 4.0were analyzed formoderately differenti-
ated CTT versus moderately differentiated necrosis versus mod-
erately differentiated D-NT but statistical signiﬁcance was not
calculated from this limited sample set consisting of only two
moderately differentiated CTT samples and a single D-NT
sample.
4) AVenndiagramwasplotted to determine the shared dysregulated
miRNAs among the groups of analyzed after ﬁltering, statistical
analysis, and fold change selection (data not shown).
Analysis Three: ICC (CTT + D-NT) versus N-NT by unpaired Student's
t-test
1) All CTT, necrotic, and D-NT samples were grouped (and referred
to as “tumor” or “ICC” as a whole) according to histological sub-
type to generate four different groups of samples: (1) N-NT,
(2) well-differentiated ICC, (3) papillary ICC and (4) moderately
differentiated ICC (Table 3, Box 3 Fig. 1).
2) When conducting unpaired Student's t-test (with Benjamini
Hochberg False Discovery Rate correction undertaken due to
multiple testing), each comparison was given its own p-valuecut, when testing the three histological subtypes of ICC versus
normal liver tissue (N-NT) by asymptotic p-value computation:
p b 0.01 was set for well-differentiated ICC versus N-NT and
p b 0.005 for papillary and moderately differentiated ICC versus
N-NT (p-values after Benjamini Hochberg False discovery rate
correction). A fold change cut-off of 2.0 between conditions
(ICC versus N-NT) was also performed.
3) A Venn diagram was plotted to show the shared dysregulated
miRNAs after ﬁltering, statistical analysis and fold change
selection (Center Box, Fig. 1).
Analysis Four: Histological subtype analysis of ICC by one-way ANOVA1) Here the subtypes of ICC (CTT, necrotic, and D-NT samples were
grouped and referred to as “tumor” or “ICC” as a whole) were
analyzed against each other (Table 3, Box 4 Fig. 1).
2) Fold change selection was performed by selecting a cut-off of 2.0
in two pairs of conditions. Further a one-way ANOVA (no
pairwise poc hoc testing) with Benjamini Hochberg False Discov-
ery Rate correctionwas performed among the pairs of conditions
by asymptotic p-value computation and p b 0.05 (p-values after
Benjamini Hochberg False discovery rate correction).
3) Signiﬁcantly dysregulated miRNAs, as determined in Analysis
Four, were plotted by Venn diagram and compared to the dys-
regulated miRNAs determined by Analysis Three for observation
of overlap (Center Box, Fig. 1).
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